Floatz logo

NOGITECAN

Peritoneal Neoplasm

Eli Lilly and CompanySmall moleculePhase 3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
51/ 100
Competitive Position
89/ 100

Competitive context

17 Active assets in the Peritoneal Neoplasm cohort.

Asset / SponsorPhaseRating
Carboplatin
Eli Lilly and Company
Phase 3BBB
DOXORUBICIN
Eli Lilly and Company
Phase 3BBB
Patupilone
Novartis Pharmaceuticals
Phase 3BB
OXALIPLATIN
Sun Yat-sen University
Phase 2/3BB
FLUOROURACILUM
AstraZeneca
Phase 2BB

View all 44 →

Same molecule, other indications

NOGITECAN is also rated in:

primary peritoneal carcinomaActive
BBB
Indicative · Phase 3
74 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative · Phase 2
72 / 100
View asset →
non-small cell lung carcinomaActive
BBB
Indicative · Phase 3
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →